Active, Not Recruiting
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
NCT03655002
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +13 more
- Locations
-
- HonorHealth Research Institute Scottsdale, Arizona, United States
- City of Hope Medical Center Duarte, California, United States
- Texas Oncology at Baylor Charles A Sammons Cancer Center Dallas, Texas, United States